210 related articles for article (PubMed ID: 12600812)
1. Tolerability of tiagabine: a prospective open-label study.
Bauer J; Bergmann A; Reuber M; Stodieck SR; Genton P
Epileptic Disord; 2002 Dec; 4(4):257-60. PubMed ID: 12600812
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of tiagabine monotherapy on cognition and mood in adult patients with chronic partial epilepsy.
Aikiä M; Jutila L; Salmenperä T; Mervaala E; Kälviäinen R
Epilepsy Behav; 2006 Jun; 8(4):750-5. PubMed ID: 16647884
[TBL] [Abstract][Full Text] [Related]
3. Tiagabine: new preparation. Refractory partial epilepsy: another alternative.
Prescrire Int; 1998 Aug; 7(36):99-101. PubMed ID: 10342943
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of adjunctive therapy with tiagabine in mentally disabled patients with epilepsy.
Chmielewska B; Stelmasiak Z
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):226-36. PubMed ID: 12898928
[TBL] [Abstract][Full Text] [Related]
5. Comparison of twice- and three times daily tiagabine for the adjunctive treatment of partial seizures in refractory patients with epilepsy: an open label, randomised, parallel-group study.
Biraben A; Beaussart M; Josien E; Pestre M; Savet JF; Schaff JL; Tourniaire D; Sevestre M; Renault-Djouadi J
Epileptic Disord; 2001 Jun; 3(2):91-100. PubMed ID: 11431171
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ
Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
[TBL] [Abstract][Full Text] [Related]
7. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF
Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011
[TBL] [Abstract][Full Text] [Related]
8. GABI-balance--a non-interventional observational study on the effectiveness of tiagabine in add-on therapy in partial epilepsy.
Chmielewska B; Stelmasiak Z
Neurol Neurochir Pol; 2008; 42(4):303-11. PubMed ID: 18975234
[TBL] [Abstract][Full Text] [Related]
9. Tiagabine: a new therapeutic option for people with intellectual disability and partial epilepsy.
Kälviäinen R
J Intellect Disabil Res; 1998 Dec; 42 Suppl 1():63-7. PubMed ID: 10030435
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the cognitive effects of tiagabine and carbamazepine as monotherapy in newly diagnosed adult patients with partial epilepsy: pooled analysis of two long-term, randomized, follow-up studies.
Aikiä M; Jutila L; Salmenperä T; Mervaala E; Kälviäinen R
Epilepsia; 2006 Jul; 47(7):1121-7. PubMed ID: 16886974
[TBL] [Abstract][Full Text] [Related]
11. Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study.
Coppola G; Grosso S; Verrotti A; Parisi P; Luchetti A; Franzoni E; Mangano S; Pelliccia A; Operto FF; Iannetti P; Curatolo P; Balestri P; Pascotto A
Epilepsy Res; 2009 Feb; 83(2-3):112-6. PubMed ID: 19081227
[TBL] [Abstract][Full Text] [Related]
12. A review of the antiepileptic drug tiagabine.
Schachter SC
Clin Neuropharmacol; 1999; 22(6):312-7. PubMed ID: 10626090
[TBL] [Abstract][Full Text] [Related]
13. A randomised open-label study of tiagabine given two or three times daily in refractory epilepsy.
Arroyo S; Boothman BR; Brodie MJ; Duncan JS; Duncan R; Nieto M; Calandre EP; Forcadas I; Crawford PM
Seizure; 2005 Mar; 14(2):81-4. PubMed ID: 15694559
[TBL] [Abstract][Full Text] [Related]
14. Tiagabine-induced generalised non convulsive status epilepticus in patients with lesional focal epilepsy.
Vinton A; Kornberg AJ; Cowley M; Matkovic Z; Kilpatrick C; O'Brien TJ
J Clin Neurosci; 2005 Feb; 12(2):128-33. PubMed ID: 15749411
[TBL] [Abstract][Full Text] [Related]
15. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced nonconvulsive status epilepticus with low dose of tiagabine.
Fitzek S; Hegemann S; Sauner D; Bönsch D; Fitzek C
Epileptic Disord; 2001 Sep; 3(3):147-50. PubMed ID: 11679307
[TBL] [Abstract][Full Text] [Related]
17. Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.
Balslev T; Uldall P; Buchholt J
Eur J Paediatr Neurol; 2000; 4(4):169-70. PubMed ID: 11008259
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures. Northern European Tiagabine Study Group.
Kälviäinen R; Brodie MJ; Duncan J; Chadwick D; Edwards D; Lyby K
Epilepsy Res; 1998 Mar; 30(1):31-40. PubMed ID: 9551842
[TBL] [Abstract][Full Text] [Related]
19. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy.
Shinnar S; Pellock JM; Conry JA
Eur J Paediatr Neurol; 2009 Jan; 13(1):3-9. PubMed ID: 18343174
[TBL] [Abstract][Full Text] [Related]
20. Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy.
Coppola G; Mangano S; Tortorella G; Pelliccia A; Fels A; Romano A; Nardello R; Habetswallner F; Licciardi F; Operto FF; Pascotto A
Epilepsy Res; 2004 Mar; 59(1):35-42. PubMed ID: 15135165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
